As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Is the Neulasta Market Poised for Significant Growth? The Neulasta market has experienced considerable expansion in recent years, with a strong historic compound annual growth rate (HCAGR). .The ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...